{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:51:25Z","timestamp":1792093885529,"version":"4.4.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"DOI":"10.1038\/s41391-026-01163-y","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:39:09Z","timestamp":1792093149000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cardiometabolic health\u2019s influence on the efficacy of pre-operative hormone therapy for men with localized high-risk prostate cancer"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-4696-3705","authenticated-orcid":false,"given":"Mitchell","family":"Boshkos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Julia","family":"Moura Nascimento Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3041-8582","authenticated-orcid":false,"given":"Rebecca S.","family":"Tidwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Venkatesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagar S.","family":"Mukhida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick G.","family":"Pilie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5208-7732","authenticated-orcid":false,"given":"Sumit K.","family":"Subudhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul G.","family":"Corn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0900-0923","authenticated-orcid":false,"given":"Ana M.","family":"Aparicio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6806-1294","authenticated-orcid":false,"given":"Bilal A.","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debanjan","family":"Pain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6757-6480","authenticated-orcid":false,"given":"Efstratios","family":"Koutroumpakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3805-7307","authenticated-orcid":false,"given":"Amado J.","family":"Zurita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0713-471X","authenticated-orcid":false,"given":"Daniel E.","family":"Frigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin R.","family":"Gregg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6365-1711","authenticated-orcid":false,"given":"Christopher J.","family":"Logothetis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes F.","family":"Fahrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4153-205X","authenticated-orcid":false,"given":"Andrew W.","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,15]]},"reference":[{"key":"1163_CR1","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1001\/jama.2025.0228","volume":"333","author":"R Raychaudhuri","year":"2025","unstructured":"Raychaudhuri R, Lin DW, Montgomery RB. Prostate cancer: a review. JAMA. 2025;333:1433\u20131446.","journal-title":"JAMA"},{"key":"1163_CR2","doi-asserted-by":"publisher","first-page":"469","DOI":"10.6004\/jnccn.2025.0052","volume":"23","author":"DE Spratt","year":"2025","unstructured":"Spratt DE, Srinivas S, Adra N, Ahmed B, An Y, Bitting R, et al. Prostate cancer, version 3.2026, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2025;23:469\u201393.","journal-title":"J Natl Compr Canc Netw"},{"key":"1163_CR3","doi-asserted-by":"publisher","first-page":"5504","DOI":"10.1200\/JCO.2020.38.15_suppl.5504","volume":"38","author":"E Efstathiou","year":"2020","unstructured":"Efstathiou E, Boukovala MA, Spetsieris N, Wen S, Hoang A, Weldon JA, et al. Neoadjuvant apalutamide (APA) plus leuprolide (LHRHa) with or without abiraterone (AA) in localized high-risk prostate cancer (LHRPC) [abstract]. 2020 ASCO Annual Meeting. J Clin Oncol. 2020;38:5504.","journal-title":"J Clin Oncol"},{"key":"1163_CR4","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.eururo.2019.05.010","volume":"76","author":"E Efstathiou","year":"2019","unstructured":"Efstathiou E, Davis JW, Pisters L, Li W, Wen S, McMullin RP, et al. Clinical and biological characterisation of localised high-risk prostate cancer: results of a randomised preoperative study of a luteinising hormone-releasing hormone agonist with or without abiraterone acetate plus prednisone. Eur Urol. 2019;76:418\u201324.","journal-title":"Eur Urol"},{"key":"1163_CR5","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1200\/JCO.18.01777","volume":"37","author":"RR McKay","year":"2019","unstructured":"McKay RR, Ye H, Xie W, Lis R, Calagua C, Zhang Z, et al. Evaluation of intense androgen deprivation before prostatectomy: a randomized phase II trial of enzalutamide and leuprolide with or without abiraterone. J Clin Oncol. 2019;37:923\u201331.","journal-title":"J Clin Oncol"},{"key":"1163_CR6","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1158\/1078-0432.CCR-16-1357","volume":"23","author":"B Montgomery","year":"2017","unstructured":"Montgomery B, Tretiakova MS, Joshua AM, Gleave ME, Fleshner N, Bubley GJ, et al. Neoadjuvant enzalutamide prior to prostatectomy. Clin Cancer Res. 2017;23:2169\u201376.","journal-title":"Clin Cancer Res"},{"key":"1163_CR7","doi-asserted-by":"publisher","first-page":"3705","DOI":"10.1200\/JCO.2013.53.4578","volume":"32","author":"ME Taplin","year":"2014","unstructured":"Taplin ME, Montgomery B, Logothetis CJ, Bubley GJ, Richie JP, Dalkin BL, et al. Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study. J Clin Oncol. 2014;32:3705\u201315.","journal-title":"J Clin Oncol"},{"key":"1163_CR8","doi-asserted-by":"publisher","unstructured":"Taplin ME, Gleave M, Shore ND, Lopez-Gitlitz A, Kretschmer A, Efstathiou E, et al. Perioperative apalutamide in high-risk localized prostate cancer. N Engl J Med. 2026. https:\/\/doi.org\/10.1056\/NEJMoa2603878.","DOI":"10.1056\/NEJMoa2603878"},{"key":"1163_CR9","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/s41585-025-01002-0","volume":"22","author":"S Tisseverasinghe","year":"2025","unstructured":"Tisseverasinghe S, Tolba M, Bahoric B, Saad F, Niazi T. Assessing the effects of prostate cancer therapies on cardiovascular health. Nat Rev Urol. 2025;22:509\u201325.","journal-title":"Nat Rev Urol"},{"key":"1163_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.eururo.2023.04.015","volume":"85","author":"CJ Logothetis","year":"2024","unstructured":"Logothetis CJ, Hahn AW. Challenging the prevailing therapeutic dogma for prostate cancer: the case for an overlap syndrome. Eur Urol. 2024;85:3\u20137.","journal-title":"Eur Urol"},{"key":"1163_CR11","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1200\/JCO.2004.03.132","volume":"22","author":"CL Amling","year":"2004","unstructured":"Amling CL, Riffenburgh RH, Sun L, Moul JW, Lance RS, Kusuda L, et al. Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol. 2004;22:439\u201345.","journal-title":"J Clin Oncol"},{"key":"1163_CR12","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1002\/ijc.22788","volume":"121","author":"E Giovannucci","year":"2007","unstructured":"Giovannucci E, Liu Y, Platz EA, Stampfer MJ, Willett WC. Risk factors for prostate cancer incidence and progression in the health professionals follow-up study. Int J Cancer. 2007;121:1571\u20138.","journal-title":"Int J Cancer"},{"key":"1163_CR13","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1158\/1055-9965.EPI-06-0754","volume":"16","author":"C Rodriguez","year":"2007","unstructured":"Rodriguez C, Freedland SJ, Deka A, Jacobs EJ, McCullough ML, Patel AV, et al. Body mass index, weight change, and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev. 2007;16:63\u201369.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"1163_CR14","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1002\/cncr.22443","volume":"109","author":"ME Wright","year":"2007","unstructured":"Wright ME, Chang SC, Schatzkin A, Albanes D, Kipnis V, Mouw T, et al. Prospective study of adiposity and weight change in relation to prostate cancer incidence and mortality. Cancer. 2007;109:675\u201384.","journal-title":"Cancer"},{"key":"1163_CR15","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1016\/j.ejca.2015.07.042","volume":"51","author":"S Antoun","year":"2015","unstructured":"Antoun S, Bayar A, Ileana E, Laplanche A, Fizazi K, di Palma M, et al. High subcutaneous adipose tissue predicts the prognosis in metastatic castration-resistant prostate cancer patients in post chemotherapy setting. Eur J Cancer. 2015;51:2570\u20137.","journal-title":"Eur J Cancer"},{"key":"1163_CR16","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/s41391-024-00870-8","volume":"28","author":"AW Hahn","year":"2025","unstructured":"Hahn AW, Tidwell RS, Pilie PG, Yu Y, Liu J, Surasi DS, et al. Body composition as a determinant of the therapeutic index with androgen signaling inhibition. Prostate Cancer Prostatic Dis. 2025;28:802\u20138.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1163_CR17","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1210\/jcem.87.2.8299","volume":"87","author":"MR Smith","year":"2002","unstructured":"Smith MR, Finkelstein JS, McGovern FJ, Zietman AL, Fallon MA, Schoenfeld DA, et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab. 2002;87:599\u2013603.","journal-title":"J Clin Endocrinol Metab"},{"key":"1163_CR18","doi-asserted-by":"crossref","unstructured":"Venkatesh N, Tidwell RS, Yu Y, Aparicio A, Zurita AJ, Subudhi SK, et al. Body composition in recurrent prostate cancer and the role of steroidogenic genotype. Endocr Relat Cancer. 2024;31:e240195.","DOI":"10.1530\/ERC-24-0195"},{"key":"1163_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17645-z","volume":"11","author":"J Vykoukal","year":"2020","unstructured":"Vykoukal J, Fahrmann JF, Gregg JR, Tang Z, Basourakos S, Irajizad E, et al. Caveolin-1-mediated sphingolipid oncometabolism underlies a metabolic vulnerability of prostate cancer. Nat Commun. 2020;11:4279.","journal-title":"Nat Commun"},{"key":"1163_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-024-00678-7","volume":"12","author":"JR Gregg","year":"2024","unstructured":"Gregg JR, Newcomb L, Wu R, Dennison J, Davis JW, Pettaway C, et al. Validation of a prognostic blood-based sphingolipid panel for men with localized prostate cancer followed on active surveillance. Biomark Res. 2024;12:134.","journal-title":"Biomark Res"},{"key":"1163_CR21","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/s41391-021-00338-z","volume":"24","author":"HM Lin","year":"2021","unstructured":"Lin HM, Huynh K, Kohli M, Tan W, Azad AA, Yeung N, et al. Aberrations in circulating ceramide levels are associated with poor clinical outcomes across localised and metastatic prostate cancer. Prostate Cancer Prostatic Dis. 2021;24:860\u201370.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1163_CR22","doi-asserted-by":"publisher","first-page":"4981","DOI":"10.1158\/0008-5472.CAN-20-3863","volume":"81","author":"LM Butler","year":"2021","unstructured":"Butler LM, Mah CY, Machiels J, Vincent AD, Irani S, Mutuku SM, et al. Lipidomic profiling of clinical prostate cancer reveals targetable alterations in membrane lipid composition. Cancer Res. 2021;81:4981\u201393.","journal-title":"Cancer Res"},{"key":"1163_CR23","doi-asserted-by":"publisher","first-page":"5005","DOI":"10.1200\/jco.2015.33.15_suppl.5005","volume":"33","author":"E Efstathiou","year":"2015","unstructured":"Efstathiou E, Li W, Gormley M, McMullin R, Ricci DS, Davis JW, et al. Biological heterogeneity in localized high-risk prostate cancer (LHRPC) from a study of neoadjuvant abiraterone acetate plus leuprolide acetate (LHRHa) versus LHRHa [abstract]. 2015 ASCO Annual Meeting. J Clin Oncol. 2015;33:5005.","journal-title":"J Clin Oncol"},{"key":"1163_CR24","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1016\/j.euo.2025.04.015","volume":"8","author":"AJ Zurita","year":"2025","unstructured":"Zurita AJ, Tidwell RS, Chapin BF, Harris DR, Zhang M, Pisters LL, et al. Randomized phase 2 trial of presurgical androgen deprivation therapy with or without axitinib in prostate cancer presenting with lymph node metastasis. Eur Urol Oncol. 2025;8:1010\u20139.","journal-title":"Eur Urol Oncol"},{"key":"1163_CR25","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1002\/jcsm.13080","volume":"13","author":"I Anyene","year":"2022","unstructured":"Anyene I, Caan B, Williams GR, Popuri K, Lenchik L, Giri S, et al. Body composition from single versus multi-slice abdominal computed tomography: concordance and associations with colorectal cancer survival. J Cachexia Sarcopenia Muscle. 2022;13:2974\u201384.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"1163_CR26","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1200\/JCO.2012.45.2722","volume":"31","author":"L Martin","year":"2013","unstructured":"Martin L, Birdsell L, Macdonald N, Reiman T, Clandinin MT, McCargar LJ, et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol. 2013;31:1539\u201347.","journal-title":"J Clin Oncol"},{"key":"1163_CR27","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1093\/jnci\/djy126","volume":"111","author":"JF Fahrmann","year":"2019","unstructured":"Fahrmann JF, Bantis LE, Capello M, Scelo G, Dennison JB, Patel N, et al. A plasma-derived protein-metabolite multiplexed panel for early-stage pancreatic cancer. J Natl Cancer Inst. 2019;111:372\u20139.","journal-title":"J Natl Cancer Inst"},{"key":"1163_CR28","doi-asserted-by":"publisher","first-page":"913","DOI":"10.3390\/cancers13040913","volume":"13","author":"JF Fahrmann","year":"2021","unstructured":"Fahrmann JF, Irajizad E, Kobayashi M, Vykoukal J, Dennison JB, Murage E, et al. A MYC-driven plasma polyamine signature for early detection of ovarian cancer. Cancers. 2021;13:913.","journal-title":"Cancers"},{"key":"1163_CR29","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1093\/jnci\/djz182","volume":"112","author":"JF Fahrmann","year":"2020","unstructured":"Fahrmann JF, Vykoukal J, Fleury A, Tripathi S, Dennison JB, Murage E, et al. Association between plasma diacetylspermine and tumor spermine synthase with outcome in triple-negative breast cancer. J Natl Cancer Inst. 2020;112:607\u201316.","journal-title":"J Natl Cancer Inst"},{"key":"1163_CR30","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/s41391-021-00481-7","volume":"25","author":"M Rivera-Izquierdo","year":"2022","unstructured":"Rivera-Izquierdo M, P\u00e9rez de Rojas J, Mart\u00ednez-Ruiz V, Arrabal-Polo M\u00c1, P\u00e9rez-G\u00f3mez B, Jim\u00e9nez-Mole\u00f3n JJ. Obesity and biochemical recurrence in clinically localised prostate cancer: a systematic review and meta-analysis of 86 490 patients. Prostate Cancer Prostatic Dis. 2022;25:411\u201321.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1163_CR31","doi-asserted-by":"publisher","first-page":"e000339","DOI":"10.1136\/bmjmed-2022-000339","volume":"2","author":"M Cariolou","year":"2023","unstructured":"Cariolou M, Markozannes G, Becerra-Tom\u00e1s N, Vieira R, Balducci K, Aune D, et al. Association between adiposity after diagnosis of prostate cancer and mortality: systematic review and meta-analysis. BMJ Med. 2023;2:e000339.","journal-title":"BMJ Med"},{"key":"1163_CR32","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1002\/cncr.23093","volume":"110","author":"JA Efstathiou","year":"2007","unstructured":"Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM, et al. Obesity and mortality in men with locally advanced prostate cancer: analysis of RTOG 85-31. Cancer. 2007;110:2691\u20139.","journal-title":"Cancer"},{"key":"1163_CR33","doi-asserted-by":"publisher","DOI":"10.1080\/21623945.2023.2201964","volume":"12","author":"T Xiong","year":"2023","unstructured":"Xiong T, Cao F, Zhu G, Ye X, Cui Y, Xing N, et al. MRI-measured periprostatic adipose tissue volume as a prognostic predictor in prostate cancer patients undergoing laparoscopic radical prostatectomy. Adipocyte. 2023;12:2201964.","journal-title":"Adipocyte"},{"key":"1163_CR34","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1200\/JCO.2009.23.2488","volume":"28","author":"DA Galv\u00e3o","year":"2010","unstructured":"Galv\u00e3o DA, Taaffe DR, Spry N, Joseph D, Newton RU. Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial. J Clin Oncol. 2010;28:340\u20137.","journal-title":"J Clin Oncol"},{"key":"1163_CR35","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/bju.15408","volume":"128","author":"CH Marshall","year":"2021","unstructured":"Marshall CH, Tunacao J, Danda V, Tsai HL, Barber J, Gawande R, et al. Reversing the effects of androgen-deprivation therapy in men with metastatic castration-resistant prostate cancer. BJU Int. 2021;128:366\u201373.","journal-title":"BJU Int"},{"key":"1163_CR36","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1002\/pros.23296","volume":"77","author":"MS Wettstein","year":"2017","unstructured":"Wettstein MS, Saba K, Umbehr MH, Murtola TJ, Fankhauser CD, Adank JP, et al. Prognostic role of preoperative serum lipid levels in patients undergoing radical prostatectomy for clinically localized prostate cancer. Prostate. 2017;77:549\u201356.","journal-title":"Prostate"},{"key":"1163_CR37","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1158\/1055-9965.EPI-14-0458","volume":"23","author":"EH Allott","year":"2014","unstructured":"Allott EH, Howard LE, Cooperberg MR, Kane CJ, Aronson WJ, Terris MK, et al. Serum lipid profile and risk of prostate cancer recurrence: results from the SEARCH database. Cancer Epidemiol Biomarkers Prev. 2014;23:2349\u201356.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"1163_CR38","doi-asserted-by":"crossref","unstructured":"Lin HM, Yang X, Centenera MM, Huynh K, Giles C, Dehairs J, et al. Circulating lipid profiles associated with resistance to androgen deprivation therapy in localized prostate cancer. JCO Precis Oncol. 2024;8:e2400260.","DOI":"10.1200\/PO.24.00260"},{"key":"1163_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103625","volume":"72","author":"HM Lin","year":"2021","unstructured":"Lin HM, Mak B, Yeung N, Huynh K, Meikle TG, Mellett NA, et al. Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase. EBioMedicine. 2021;72:103625.","journal-title":"EBioMedicine"},{"key":"1163_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06804-5","volume":"15","author":"M Yang","year":"2024","unstructured":"Yang M, Wei X, Yi X, Jiang DS. Mitophagy-related regulated cell death: molecular mechanisms and disease implications. Cell Death Dis. 2024;15:505.","journal-title":"Cell Death Dis"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01163-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01163-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01163-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:39:11Z","timestamp":1792093151000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01163-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,15]]},"references-count":40,"alternative-id":["1163"],"URL":"https:\/\/doi.org\/10.1038\/s41391-026-01163-y","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,15]]},"assertion":[{"value":"8 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AWH reports consulting to Janssen, Intellisphere, AVEO, Exelixis, Eisai, Pfizer, and Tolmar; honoraria from Medscape, Binaytara Foundation, Projects in Knowledge, Curio Science, Dava Oncology, IDEOlogy Health, MJH Life Sciences, and Mashup Media; and institutional research funding from Bayer, Bristol Myers Squibb, Eisai, and Halda Therapeutics. BAS reports consulting to Amgen, Astellas, Bayer, Merck, Pfizer, Johnson & Johnson, and SurvivorNet; honoraria from Cancer Expert Now, Cincinnati Cancer Advisors, Curio Science, CardinalHealth, DAVA Oncology, and IDEOlogy Health; and institutional research funding from Amgen, Johnson & Johnson, and Regeneron. DEF has a familial relationship with March Biosciences, Biocity Biopharmaceuticals, and Barricade Therapeutics. The remaining co-authors have no conflicts to disclose.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations, including the Declaration of Helsinki. This post hoc analysis and the associated translational studies were approved by the Institutional Review Board of The University of Texas MD Anderson Cancer Center (protocols PA16-0736 and 2025-0232). Each parent clinical trial (NCT03279250, NCT01409200, NCT01088529) was approved by the same Institutional Review Board. Informed consent was obtained from all participants, who provided written informed consent at enrollment in the parent clinical trials. No identifiable images of human research participants are included in this manuscript.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}]}}